XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments
6 Months Ended
Jun. 30, 2020
Investments, All Other Investments [Abstract]  
Financial Instruments Financial Instruments
The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of June 30, 2020 and as of December 31, 2019 are presented in the following tables:
June 30, 2020
Amortized CostUnrealized GainsUnrealized LossesFair Value
(in thousands)
Money market funds$256,773  $—  $—  $256,773  
Commercial paper79,822  90  (2) 79,910  
Corporate bonds290,898  1,205  (48) 292,055  
U.S. treasury securities422,592  907  (13) 423,486  
U.S. agency securities34,479  137  (2) 34,614  
Total cash equivalents and investments$1,084,564  $2,339  $(65) $1,086,838  
Classified as:
Cash equivalents$256,773  
Short-term investments619,271  
Long-term investments210,794  
Total cash equivalents and investments$1,086,838  
December 31, 2019
Amortized CostUnrealized GainsUnrealized LossesFair Value
(in thousands)
Money market funds$122,900  $—  $—  $122,900  
Corporate bonds204,144  871  (4) 205,011  
U.S. treasury securities181,340  557  (3) 181,894  
U.S. agency securities25,658  167  (1) 25,824  
Certificates of deposit1,000  —  —  1,000  
Total cash equivalents and investments$535,042  $1,595  $(8) $536,629  
Classified as:
Cash equivalents$122,900  
Short-term investments355,407  
Long-term investments58,322  
Total cash equivalents and investments$536,629  
As of June 30, 2020, the remaining contractual maturities of available-for-sale securities were less than 3 years. There have been no significant realized losses on available-for-sale securities for the periods presented. As of June 30, 2020, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company’s marketable securities are due to market factors. To date, the Company has not recorded any impairment charges on marketable securities.